Psilocybin - A Drug to be Considered for the Treatment of Anxiety and Depression in Cancer Patients

Jump To References Section

Authors

  • Suresh Velumani
     Sumandeep Nursing College, Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara - 391760, Gujarat ,IN
  • Jitendra D. Lakhani
     Department of General Medicine, SBKSMI and RC, Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara - 391760, Gujarat ,IN
  • Ramachandran Balaraman
     Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara - 391760, Gujarat ,IN

DOI:

https://doi.org/10.18311/jnr/2024/35676

Keywords:

Anti-anxiety, Anti-depressant, Cancer, Psilocybin

Abstract

Cancer patients are more vulnerable to developing psychiatric disorders like anxiety and depression. These conditions give an additional burden leading to poor quality of life. The available antidepressant and antianxiety drugs are not very useful in improving quality of life by reducing anxiety and depressive episodes. Therefore, there is a need for good drugs to alleviate the psychiatric problems among cancer patients. The recent reviews deal with the pharmacodynamics, pharmacokinetics and efficacy of psilocybin in the treatment of patients suffering from anxiety and depression.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Downloads

Published

2024-07-31

How to Cite

Velumani, S., Lakhani, J. D., & Balaraman, R. (2024). Psilocybin - A Drug to be Considered for the Treatment of Anxiety and Depression in Cancer Patients. Journal of Natural Remedies, 24(7), 1487–1492. https://doi.org/10.18311/jnr/2024/35676

Issue

Volume 24, Issue 7, July 2024

Section

Short Review

Categories

License

Copyright (c) 2024 Suresh Velumani, Jitendra D. Lakhani, Ramachandran Balaraman (Author)

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Crossref
Scopus
Google Scholar
Europe PMC
Received 2023-11-22
Accepted 2024-06-17
Published 2024-07-31

 

References

Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011; 21(9):655-79. https://doi.org/10.1016/j.euroneuro.2011.07.018 PMid:21896369 DOI: https://doi.org/10.1016/j.euroneuro.2011.07.018

Belouin SJ, Henningfield JE. Psychedelics: Where we are now, why we got here, what we must do. Neuropharmacol. 2018; 142:7-19. https://doi.org/10.1016/j.neuropharm.2018.02.018 PMid:29476779 DOI: https://doi.org/10.1016/j.neuropharm.2018.02.018

Breitbart W, Rosenfeld B, Pessin H, Kaim M, Funesti-Esch J, Galietta M, et al. Depression, hopelessness, and desire for hastened death in terminally ill patients with cancer. Jama. 2000; 284(22):2907-11. https://doi.org/10.1001/jama.284.22.2907 PMid:11147988 DOI: https://doi.org/10.1001/jama.284.22.2907

Passik SD, Kirsh KL, Rosenfeld B, McDonald MV, Theobald DE. The changeable nature of patients’ fears regarding chemotherapy: Implications for palliative care. J Pain Symptom manage. 2001; 21(2):113-20. https://doi.org/10.1016/S0885-3924(00)00249-9 PMid:11226762 DOI: https://doi.org/10.1016/S0885-3924(00)00249-9

Groenvold M, Petersen MA, Idler E, Bjorner JB, Fayers PM, Mouridsen HT. Psychological distress and fatigue predicted recurrence and survival in primary breast cancer patients. Breast Cancer Res Treat. 2007; 105(2):209-19. https://doi.org/10.1007/s10549-006-9447-x PMid:17203386 DOI: https://doi.org/10.1007/s10549-006-9447-x

Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol. 2016; 30(12):1181-97. https://doi.org/10.1177/0269881116675513 PMid:27909165 PMCid:PMC5367557 DOI: https://doi.org/10.1177/0269881116675513

Grassi L, Spiegel D, Riba M. Advancing psychosocial care in cancer patients. F1000Research. 2017; 6:2083. https://doi.org/10.12688/f1000research.11902.1 PMid:29259774 PMCid:PMC5717468 DOI: https://doi.org/10.12688/f1000research.11902.1

Freedman RA, Kouri EM, West DW, Lii J, Keating NL. Association of breast cancer knowledge with receipt of guideline-recommended breast cancer treatment. J Oncol Pract. 2016; 12(6):e613-25. https://doi.org/10.1200/JOP.2015.008508 PMid:27165488 PMCid:PMC4957257 DOI: https://doi.org/10.1200/JOP.2015.008508

Bakhiet TE, Ali SM, Bakhiet AM. Prevalence of depression and anxiety among adult patients undergoing chemotherapy in Khartoum, Sudan: A cross-sectional study. J Affect Disord Reports. 2021; 6:100218. https://doi.org/10.1016/j.jadr.2021.100218 DOI: https://doi.org/10.1016/j.jadr.2021.100218

Riblet N, Larson R, Watts BV, Holtzheimer P. Reevaluating the role of antidepressants in cancer-related depression: A systematic review and meta-analysis. Gen Hosp Psychiatry. 2014; 36(5):466-73. https://doi.org/10.1016/j.genhosppsych.2014.05.010 PMid:24950919 DOI: https://doi.org/10.1016/j.genhosppsych.2014.05.010

Boekhout AH, Vincent AD, Dalesio OB, Van Den Bosch J, Foekema-Töns JH, Adriaansz S, et al. Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: A randomized, double-blind, placebo-controlled trial. J Clin Onco. 2011; 29(29):3862-8. https://doi.org/10.1200/JCO.2010.33.1298 PMid:21911720 DOI: https://doi.org/10.1200/JCO.2010.33.1298

Fisch MJ, Loehrer PJ, Kristeller J, Passik S, Jung SH, Shen J, et al. Fluoxetine versus placebo in advanced cancer outpatients: A double-blinded trial of the Hoosier Oncology Group. J Clin Onco. 2003; 21(10):1937-43. https://doi.org/10.1200/JCO.2003.08.025 PMid:12743146 DOI: https://doi.org/10.1200/JCO.2003.08.025

Lydiatt WM, Denman D, McNeilly DP, Puumula SE, Burke WJ. A randomized, placebo-controlled trial of citalopram for the prevention of major depression during treatment for head and neck cancer. Arch Otorhinolaryngol. 2008; 134(5):528-35. https://doi.org/10.1001/archotol.134.5.528 PMid:18490576 DOI: https://doi.org/10.1001/archotol.134.5.528

Lydiatt WM, Bessette D, Schmid KK, Sayles H, Burke WJ. Prevention of depression with escitalopram in patients undergoing treatment for head and neck cancer: Randomized, double-blind, placebo-controlled clinical trial. JAMA Otolaryngology. 2013; 139(7):678-86.

Ostuzzi G, Matcham F, Dauchy S, Barbui C, Hotopf M. Antidepressants for the treatment of depression in people with cancer. Cochrane Database Syst Rev. 2018; 2018(4):CD011006. https://doi.org/10.1002/14651858.CD011006.pub3 PMid:29683474 PMCid:PMC6494588 DOI: https://doi.org/10.1002/14651858.CD011006.pub3

National Center for Biotechnology Information. PubChem Compound Summary for CID 10624, Psilocybine. Retrieved April 25, 2022. Available from https://pubchem.ncbi.nlm.nih.gov/compound/Psilocybine

Gibbons S, Arunotayanun W. Natural product (fungal and herbal) novel psychoactive substances. In Novel psychoactive substances. Academic Press. 2013. p. 345-362. https://doi.org/10.1016/B978-0-12-415816-0.00014-6 PMid:23541009 DOI: https://doi.org/10.1016/B978-0-12-415816-0.00014-6

Passie T, Seifert J, Schneider U, Emrich HM. The pharmacology of psilocybin. Addict Biol. 2002; 7(4):357-64. https://doi.org/10.1080/1355621021000005937 PMid:14578010 DOI: https://doi.org/10.1080/1355621021000005937

“Psilocybin Fast Facts”. National Drug Intelligence Center. Archived from the original on May 12, 2007. Retrieved April 4, 2007.

Van Amsterdam J, Opperhuizen A, van den Brink W. Harm potential of magic mushroom use: A review. Regul Toxicol Pharmacol. 2011; 59(3):423-9. https://doi.org/10.1016/j.yrtph.2011.01.006 PMid:21256914 DOI: https://doi.org/10.1016/j.yrtph.2011.01.006

Wittmann M, Carter O, Hasler F, Cahn BR, Grimberg U, Spring P, et al. Effects of psilocybin on time perception and temporal control of behaviour in humans. J Psychopharmacol. 2007; 21(1):50-64. https://doi.org/10.1177/0269881106065859 PMid:16714323 DOI: https://doi.org/10.1177/0269881106065859

Schultes, Richard Evans. Hallucinogenic Plants. Illustrated by Elmer W. Smith. New York: Golden Press. 1976. p. 68. ISBN 978-0-307-24362-1.

Carhart-Harris RL, Erritzoe D, Williams T, Stone JM, Reed LJ, Colasanti A, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings National Acad Sci. 2012; 109(6):2138-43. https://doi.org/10.1073/pnas.1119598109 PMid:22308440 PMCid:PMC3277566 DOI: https://doi.org/10.1073/pnas.1119598109

Kraehenmann R, Preller KH, Scheidegger M, Pokorny T, Bosch OG, Seifritz E, et al. Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biological Psychiatry. 2015; 78(8):572-81. https://doi.org/10.1016/j.biopsych.2014.04.010 PMid:24882567 DOI: https://doi.org/10.1016/j.biopsych.2014.04.010

DeRubeis RJ, Siegle GJ, Hollon SD. Cognitive therapy versus medication for depression: Treatment outcomes and neural mechanisms. Nature Reviews Neuroscience. 2008; 9(10):788-96. https://doi.org/10.1038/nrn2345 PMid:18784657 PMCid:PMC2748674 DOI: https://doi.org/10.1038/nrn2345

Carhart-Harris RL, Erritzoe D, Williams T, Stone JM, Reed LJ, Colasanti A, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings National Acad Sci. 2012; 109(6):2138-44. https://doi.org/10.1073/pnas.1119598109 PMid:22308440 PMCid:PMC3277566 DOI: https://doi.org/10.1073/pnas.1119598109

Raichle ME. The neural correlates of consciousness: an analysis of cognitive skill learning. Philosophical Transactions of the Royal Society of London. Series B. Biological Sciences. 1998; 353(1377):1889-901. https://doi.org/10.1098/rstb.1998.0341 PMid:9854261 PMCid:PMC1692415 DOI: https://doi.org/10.1098/rstb.1998.0341

Passie T, Seifert J, Schneider U, Emrich HM. The pharmacology of psilocybin. Addict Biol. 2002; 7(4):357-64. https://doi.org/10.1080/1355621021000005937 PMid:14578010 DOI: https://doi.org/10.1080/1355621021000005937

Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011; 68(1):71-8. https://doi.org/10.1001/archgenpsychiatry.2010.116 PMid:20819978 DOI: https://doi.org/10.1001/archgenpsychiatry.2010.116

Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. J Psychopharmacol. 2016; 30(12):1165-80. https://doi.org/10.1177/0269881116675512 PMid:27909164 PMCid:PMC5367551 DOI: https://doi.org/10.1177/0269881116675512

Agin-Liebes GI, Malone T, Yalch MM, Mennenga SE, Ponté KL, Guss J, et al. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol. 2020; 34(2):155-66. https://doi.org/10.1177/0269881119897615 PMid:31916890 DOI: https://doi.org/10.1177/0269881119897615

Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol. 2016; 30(12):1181-97. https://doi.org/10.1177/0269881116675513 PMid:27909165 PMCid:PMC5367557 DOI: https://doi.org/10.1177/0269881116675513

Most read articles by the same author(s)

1 2 > >>